Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Bcl-2/bcl-xl Inhibitor 1
2. Apg-2575
3. 2180923-05-9
4. Osl3fez1if
5. Apg2575
6. 4-[4-[[8-(4-chlorophenyl)spiro[3.5]non-7-en-7-yl]methyl]piperazin-1-yl]-n-[4-[[(2s)-1,4-dioxan-2-yl]methylamino]-3-nitrophenyl]sulfonyl-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
7. Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-n-((4-(((2s)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-
8. Unii-osl3fez1if
9. Lisaftoclax [inn]
10. Lisaftoclax [who-dd]
11. Schembl20580489
12. Us10221174, Compound 6
13. Bdbm361577
14. Glxc-25842
15. Ex-a6915
16. Nsc837893
17. Nsc-837893
18. Hy-129179
19. Cs-0103865
20. (s)-n-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- Nitrophenyl)sulfonyl)-2-((1h-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- En-7-yl)methyl)piperazin-1-yl)benzamide
21. 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-piperazin-1-yl)-n-((3-nitro-4-(((2s)-1,4-dioxan-2-ylmethyl)amino)phenyl)sulfonyl)-2-(1hpyrrolo(2,3-b)pyridin-5-yloxy)benzamide
Molecular Weight | 882.4 g/mol |
---|---|
Molecular Formula | C45H48ClN7O8S |
XLogP3 | 7.5 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 12 |
Exact Mass | 881.2973604 g/mol |
Monoisotopic Mass | 881.2973604 g/mol |
Topological Polar Surface Area | 192 Ų |
Heavy Atom Count | 62 |
Formal Charge | 0 |
Complexity | 1690 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
23
PharmaCompass offers a list of Lisaftoclax API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lisaftoclax manufacturer or Lisaftoclax supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lisaftoclax manufacturer or Lisaftoclax supplier.
PharmaCompass also assists you with knowing the Lisaftoclax API Price utilized in the formulation of products. Lisaftoclax API Price is not always fixed or binding as the Lisaftoclax Price is obtained through a variety of data sources. The Lisaftoclax Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lisaftoclax manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lisaftoclax, including repackagers and relabelers. The FDA regulates Lisaftoclax manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lisaftoclax API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lisaftoclax supplier is an individual or a company that provides Lisaftoclax active pharmaceutical ingredient (API) or Lisaftoclax finished formulations upon request. The Lisaftoclax suppliers may include Lisaftoclax API manufacturers, exporters, distributors and traders.
Lisaftoclax Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lisaftoclax GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lisaftoclax GMP manufacturer or Lisaftoclax GMP API supplier for your needs.
A Lisaftoclax CoA (Certificate of Analysis) is a formal document that attests to Lisaftoclax's compliance with Lisaftoclax specifications and serves as a tool for batch-level quality control.
Lisaftoclax CoA mostly includes findings from lab analyses of a specific batch. For each Lisaftoclax CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lisaftoclax may be tested according to a variety of international standards, such as European Pharmacopoeia (Lisaftoclax EP), Lisaftoclax JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lisaftoclax USP).